Dexamethasone as an Immediate Intervention
Withdrawn
To determine if a single dose of dexamethasone (5 mg) administered in the first 12 hours following a potentially traumatic event alters a) cortisol and FKBP5 RNA the next day in the periphery measured in saliva; b) FKBP5 methylation by 1 month; c) executive functioning and emotion regulation functioning; d) psychophysiological (heart rate, respiration, skin conductance) in response cued reminders of the trauma; e) enhances the likelihood of remission of PTSD symptom severity.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
12/12/2017
Locations: New York University Medical Center, New York, New York
Conditions: Trauma
Particulate vs. Nonparticulate Epidural Steroid Injections for Lumbar Foraminal Stenosis
Withdrawn
Chronic lumbosacral radiculopathy secondary to lumbar spinal stenosis affects a large number of individuals, and there is a general lack of consensus in the medical community in terms of effective treatments for this problem. By assessing the relative efficacy of transforaminal epidural injections of particulate and nonparticulate steroids, this study attempts to further define the appropriate conservative management of painful unilateral radiculopathies due to unilateral lumbar foraminal stenos... Read More
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
12/04/2017
Locations: Hospital for Special Surgery, New York, New York
Conditions: Lumbar Spinal Stenosis
A Safety Study of Carfilzomib in Patients With Previously-Treated Systemic Light Chain Amyloidosis
Completed
This is a dose finding study to evaluate the safety and determine the maximum tolerated dose of carfilzomib in patients with previously treated systemic light-chain amyloidosis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/16/2017
Locations: Columbia University, New York, New York +1 locations
Conditions: Amyloidosis, Systemic Light Chain Amyloidosis
CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
Completed
Randomized subjects will receive CC-5013 plus high-dose dexamethasone or placebo appearing identical to CC-5013 plus high-dose dexamethasone in 4-week cycles. Each subject will participate in a treatment phase and a follow-up phase.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/18/2017
Locations: Roswell Park Cancer Institute, Buffalo, New York +4 locations
Conditions: Multiple Myeloma
Study of Elotuzumab in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma and Various Levels of Renal Function
Completed
The purpose of the study is to assess the concentration of Elotuzumab in Myeloma patients with very low kidney function including patients on dialysis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/27/2017
Locations: Weill Cornell Medical College, New York, New York +1 locations
Conditions: Multiple Myeloma
Combination of Revlimid, Melphalan and Dexamethasone as First Line Treatment for Multiple Myeloma
Terminated
This study is to determine whether addition of Revlimid to standard therapy will increase overall and complete response rates compared to historical standard frontline therapy and whether this combination treatment has fewer side effects than similar combination induction treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/21/2017
Locations: Bellevue Hospital, New York, New York +2 locations
Conditions: Multiple Myeloma
Phase II Study of Velcade, Decadron, and Doxil Followed by Cyclophosphamide in Multiple Myeloma
Completed
PRIMARY STUDY OBJECTIVES * To evaluate the efficacy of the combination of bortezomib, dexamethasone, with and without DOXIL, followed by high-dose cyclophosphamide as a therapy for two different subsets of multiple myeloma patients: 1. Patients post first line therapy 2. Patients with relapsed/refractory disease who are bortezomib-naïve * To evaluate the safety of the combination of bortezomib and dexamethasone, with and without DOXIL, followed by high-dose cyclophosphamide as therapy for... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/19/2017
Locations: Weill Medical College of Cornell University, New York, New York
Conditions: Multiple Myeloma
Prolonged Popliteal Fossa Nerve Blockade (Prolonged Pop)
Completed
This study looks at addition of medications to the local anesthetic for the nerve blockade.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
05/22/2017
Locations: Hospital For Special Surgery, New York, New York
Conditions: Postoperative Pain
Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies
Completed
The purpose of this study is to test the safety and tolerability of carfilzomib at different dose levels on hematological cancers such as multiple myeloma, non-Hodgkin's lymphoma, Hodgkin's disease, or Waldenstrom's macroglobulinemia. Carfilzomib is a proteasome inhibitor, an enzyme responsible for degrading a wide variety of cellular proteins.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/28/2017
Locations: Memorial Sloan Kettering Cancer Center, New York, New York +2 locations
Conditions: Waldenstrom's Macroglobulinemia, Non-Hodgkin's Lymphoma, Hodgkin's Disease, Multiple Myeloma
Phase 1b Multicenter Study of Carfilzomib With Lenalidomide and Dexamethasone in Relapsed Multiple Myeloma
Completed
To evaluate the safety and maximum tolerated dose (MTD) of carfilzomib in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/28/2017
Locations: Cornell University, New York, New York
Conditions: Relapsed Multiple Myeloma
A Multicenter, Open-label, Phase 1b Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Subjects
Completed
The primary objective was to determine the maximum tolerated dose of carfilzomib given twice weekly in combination with cyclophosphamide and dexamethasone for patients with newly diagnosed multiple myeloma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/28/2017
Locations: Clinical Research Alliance, New York, New York
Conditions: Multiple Myeloma
Pomalidomide in Combination With High Dose Dexamethasone and Oral Cyclophosphamide
Completed
The main purpose of this study is to see whether pomalidomide can help people with myeloma. Researchers also want to find out if pomalidomide is safe and tolerable.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/18/2017
Locations: Mount Sinai School of Medicine, The Tisch Cancer Institute, New York, New York
Conditions: Myeloma